HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study)

Autor:	Hasson, H., Galli, L., Gallotta, G., Neri, V., Blanc, P., D Annunzio, M., Morsica, G., Sollima, S., Marco Merli, Lazzarin, A., Uberti-Foppa, C.
Přispěvatelé:	Hasson, Hamid, Galli, Laura, Gallotta, Giulia, Neri, Valentina, Blanc, Perluigi, D'Annunzio, Marco, Morsica, Giulia, Sollima, Salvatore, Merli, Marco, Lazzarin, Adriano, UBERTI FOPPA, Caterina
Předmět:	Adult Male Hepaciviru Ritonavir Coinfection Anti-HIV Agent Middle Aged Hepatitis C Lopinavir Prospective Studie Young Adult Antiretroviral Therapy Highly Active HIV-1 Female HIV Infection Pilot Project Human
Zdroj:	Europe PubMed Central Scopus-Elsevier
Popis:	The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week toxicity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naive to anti- HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::74c6fadd9c8a30def07ea7fa69cf1b24 http://europepmc.org/abstract/med/23109014 Zobrazit plný text záznamu